arm, and it showed no statistical difference between CABG and medical therapy on 5-year mortality, although acute myocardial infarctions were more common in the medical therapy arm.
The fact that modern trials have been designed without a medical therapy arm makes me wonder how often that option is minimized or omitted in discussions with patients with preserved ejection fraction. This deficiency in the trial design reflects a weakness of actual practice. Although when PCI was first introduced in the 1980s it was said that it would replace CABG, in current practice, it is being used instead of medical therapy, often before medical therapy is even attempted. This is particularly problematic because some patients who are unwilling to have surgery may agree to a percutaneous procedure, even though it may have a greater mortality risk than CABG and may cause them greater harm than medical therapy. They might make a different decision if they knew that medical therapy was a viable option.
Meta-analysis is a powerful tool for combining data across studies. As is the case in this study, the larger sample sizes enable us to answer questions we otherwise could not. Now we need to ensure that our studies and our patient discussions include all the viable treatment options. 
